While two Maryland companies recently reported more progress in their years-long quest to develop a new anthrax vaccine and corner the federal market for the biodefense prophylactic, a newer player got a big boost this week.
( ECCO-the European CanCer Organisation ) Inhibiting a protein involved in bone metabolism can delay the onset of bone metastases common in men with prostate cancer resistant to hormone treatment. The research on the effects of the monoclonal antibody den
Stockholm, Sweden: Inhibiting a protein involved in bone metabolism can delay the onset of the bone metastases which are common in men with a particular form of prostate cancer, a researcher will tell the 2011 European Multidisciplinary Cancer Congress to
Denosumab inhibits RANKL, a protein involved in bone metabolism, and appears to delay bone metastases onset in patients with prostate cancer, researchers from the Georges Pompidou Hospital, Paris, France, reported at the European Multidisciplinary Cancer